Yahoo! Finance Search - Finance Home - Yahoo! - Help

Friday, December 9 2016 3:02am ET - U.S. Markets open in 6 hours and 28 minutes.
Industry Center - Drug Delivery
Industry Center > Drug Delivery > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Delivery News
Latest News
Thursday, Dec 8, 2016
·Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118
CNW Group - Thu 11:55 am ET
·Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118
PR Newswire - Thu 11:55 am ET
·Bill Ackman's Pershing Square Q3 Shareholder Letter Weighs In On Valeant, Chipotle
- Thu 10:16 am ET
·Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST® From Valeant
PR Newswire - Thu 1:00 am ET
Tuesday, Dec 6, 2016
·Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Tue Dec 6
Monday, Dec 5, 2016
·Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV)
at Investopedia - Mon Dec 5
Saturday, Dec 3, 2016
·Aradigm Lung Infection Antibiotic Fails Trial (ARDM)
at Investopedia - Fri Dec 2
Thursday, Dec 1, 2016
·Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials
at MarketWatch - Thu Dec 1
·Valeant Stock Plunges 11% on Failed Salix Sale (VRX)
at Investopedia - Thu Dec 1
·Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa
Business Wire - Thu Dec 1
·SEC Discloses Correspondence Over Valeant's Accounting Practices
at TheStreet.com - Wed Nov 30
·Valeant, Salix, Sales Force and Asset Sales
- Wed Nov 30
Wednesday, Nov 30, 2016
·Valeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?!
at Barrons.com - Wed Nov 30
·[$$] Valeant's talks to sell Salix unit for $10bn break down
at FT.com - Wed Nov 30
·Why Valeant is Crumbling
at Barrons.com - Wed Nov 30
·Valeant Plummets on Reports of Salix Takeover Breakdown
at TheStreet.com - Wed Nov 30
·It looks like a key Valeant deal might be falling apart, and now the stock is tanking
Business Insider - Wed Nov 30
·Uh Oh, Valeant's Hiring. Why That's Very Bad News.
at Barrons.com - Wed Nov 30
·Delcath Systems to Present at the 9th Annual LD Micro Main Event
- Wed Nov 30
·Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor®
PR Newswire - Tue Nov 29
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Delivery Headlines
More Finance RSS Feeds


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?